Trial reportBiological psychiatry2014
Pretreatment brain states identify likely nonresponse to standard treatments for depression.
Trial report in Biological psychiatry, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed.
- Optimizing outcomes, mechanisms, and recall of Cognitive Therapy for depression: Dose of constructive memory support strategies.Behaviour research and therapy · 2023Trial
- Serial Mediators of Memory Support Strategies Used With Cognitive Therapy for Depression: Improving Outcomes Through Patient Adherence and Treatment Skills.Behavior therapy · 2023Trial
- Anterior cingulate cortex activation during attentional control as a transdiagnostic marker of psychotherapy response: a randomized clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022Trial
- Metabolic activity in subcallosal cingulate predicts response to deep brain stimulation for depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2020Trial
- Attentional bias modification is associated with fMRI response toward negative stimuli in individuals with residual depression: a randomized controlled trialJournal of psychiatry & neuroscience : JPN · 2020Trial
- Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study.Translational psychiatry · 2019Trial
- Rostral Anterior Cingulate Cortex Morphology Predicts Treatment Response to Internet-Based Cognitive Behavioral Therapy for Depression.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2018Trial
- Trial
- Functional Connectivity of the Subcallosal Cingulate Cortex And Differential Outcomes to Treatment With Cognitive-Behavioral Therapy or Antidepressant Medication for Major Depressive Disorder.The American journal of psychiatry · 2017Trial
- Treating major depression with yoga: A prospective, randomized, controlled pilot trial.PloS one · 2017Trial
- Preliminary Findings Supporting Insula Metabolic Activity as a Predictor of Outcome to Psychotherapy and Medication Treatments for Depression.The Journal of neuropsychiatry and clinical neurosciences · 2015Trial
- Neural activity during attentional conflict predicts reduction in tinnitus perception following rTMS.Brain stimulationTrial
- Developing Clinically Interpretable Neuroimaging Biotypes in Psychiatry.Biological psychiatry · 2026Review
- Frontal Cortex Stimulation Modulates Attentional Circuits and Increases Anxiety-Potentiated Startle in Anxious Depression.Biological psychiatry. Cognitive neuroscience and neuroimaging · 2025Article
- Breakthroughs and challenges for generating brain network-based biomarkers of treatment response in depression.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Blunted stimulus-preceding negativity during reward anticipation in major depressive disorder.Journal of affective disorders · 2024Article
- The capacity of brain circuits to enhance psychiatry.Nature medicine · 2024Article
- The Role of Subgenual Resting-State Connectivity Networks in Predicting Prognosis in Major Depressive Disorder.Biological psychiatry global open science · 2024Article
- Meloxicam Targets COX-2/NOX1/NOX4/Nrf2 Axis to Ameliorate the Depression-like Neuropathology Induced by Chronic Restraint Stress in Rats.Pharmaceuticals (Basel, Switzerland) · 2023Article
- Balancing the beautiful and the good in pursuit of biomarkers for depression.World psychiatry : official journal of the World Psychiatric Association (WPA) · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundTreatment approaches for major depressive disorder (MDD) result in approximately one third of patients achieving remission after a first treatment. Added treatment generally improves remission rates, but approximately one third of all patients fail to respond after several treatments (sequential monotherapies or combined treatment). A pretreatment biomarker could help identify these patients. Overactivity of the subcallosal cingulate has been associated with failure of response to treatment in MDD, and it is a potential candidate for such a biomarker.
methodsInvestigators enrolled 82 patients with MDD currently not receiving treatment in a two-phase treatment study. Patients underwent a fluorodeoxyglucose positron emission tomography scan. After scanning, patients were randomly assigned to 12 weeks of treatment with either escitalopram or cognitive-behavioral therapy (CBT). Patients not achieving remission after 12 weeks of initial treatment were treated with an additional 12 weeks of escitalopram plus CBT. Subcallosal cingulate metabolism was compared between patients who failed to achieve a response and patients who achieved remission as a result of either phase one or phase two treatment. This analysis was followed by a whole-brain analysis making the same comparison.
resultsAfter two phases of treatment (24 weeks), 36 patients were identified as remitters, 6 patients were responders, and 9 patients were nonresponders. Subcallosal cingulate metabolism was significantly higher in nonresponders than remitters. In the follow-up whole-brain analysis, increased superior temporal sulcus activity was also associated with nonresponse to two treatments.
conclusionsPatients with MDD who fail to achieve remission as a result of CBT or escitalopram, either alone or in combination, have a distinct brain metabolic pattern compared with patients who achieve remission as a result of CBT, escitalopram, or their combination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.